| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Mar 22, 2017 | ESPR Esperion Therapeutics, Inc. | Goldstein Dov A Md | Director | Sell | 800,000 | $41.66 | $33,327,088.28 | -28.7% | |
| Mar 21, 2017 | CPIX Cumberland Pharmaceuticals Inc | Krogulski Kenneth55 | Director | Buy | 15,000 | $6.53 | $97,950.00 | +11.1% | |
| Mar 21, 2017 | ESPR Esperion Therapeutics, Inc. | Janney Daniel | Director | Sell | 350,000 | $45.80 | $16,029,262.91 | -4.6% | |
| Mar 21, 2017 | EGRX Eagle Pharmaceuticals, Inc. | Pernock David | Pres. &Chief Comm. Officer | Buy | 61 | $83.98 | $5,122.78 | +13.6% | |
| Mar 21, 2017 | ESPR Esperion Therapeutics, Inc. | Omenn Gilbert S | Director | Buy | 1,000 | $42.26 | $42,260.00 | New | |
| Mar 21, 2017 | ALKS Alkermes Plc. | Cooke Shane62 | President, Alkermes Plc | Sell | 1,900 | $60.09 | $114,162.40 | -1.3% | |
| Mar 20, 2017 | PAHC Phibro Animal Health Corp | Carlson Gerald K | Director | Sell | 12,000 | $28.13 | $337,560.00 | -100% | |
| Mar 20, 2017 | BCRX Biocryst Pharmaceuticals Inc | Staab Thomas R II | Senior Vice President And CFO | Sell | 3,250 | $9.20 | $29,900.00 | -2.2% | |
| Mar 20, 2017 | EGRX Eagle Pharmaceuticals, Inc. | Proquest Investments Iv, L.P. | 10% Owner | Sell | 100,000 | $82.06 | $8,206,307.87 | -0.9% | |
| Mar 17, 2017 | LNTH Lantheus Holdings, Inc. | Burgstahler David F | Director, 10% Owner | Sell | 3,000,000 | $12.20 | $36,600,000.00 | -19.6% | |
| Mar 17, 2017 | LNTH Lantheus Holdings, Inc. | Avista Capital Partners Gp, LLC | 10% Owner | Sell | 3,000,000 | $12.20 | $36,600,000.00 | -19.6% | |
| Mar 17, 2017 | LNTH Lantheus Holdings, Inc. | Venkataraman Sriram | Director, 10% Owner | Sell | 3,000,000 | $12.20 | $36,600,000.00 | -19.6% | |
| Mar 16, 2017 | RMTI Rockwell Medical, Inc. | Holt Kenneth L | Director | Sell | 6,000 | $5.98 | $35,871.08 | -8.7% | |
| Mar 15, 2017 | ALKS Alkermes Plc. | Ehrich Elliot | EVP, R&D &CMO, Alkermes, Inc. | Sell | 11,000 | $56.74 | $624,107.24 | -8.6% | |
| Mar 15, 2017 | NVS Novartis AG | Novartis Bioventures Ltd | 10% Owner | Buy | 560,000 | $5.00 | $2,800,000.00 | +10.7% | |
| Mar 15, 2017 | LNTH Lantheus Holdings, Inc. | Healey Timothy G | SVP, Commercial | Sell | 11,314 | $12.42 | $140,554.95 | -12.0% | |
| Mar 15, 2017 | BHC Bausch Health Companies Inc. | De Schutter Richard U | Director | Buy | 10,000 | $10.80 | $108,000.00 | +65.8% | |
| Mar 14, 2017 | BHC Bausch Health Companies Inc. | Valueact Holdings, L.P.73 | Director, See Remarks | Buy | 3,000,000 | $10.82 | $32,465,000.00 | +10.6% | |
| Mar 14, 2017 | IRWD Ironwood Pharmaceuticals Inc | Currie Mark G53 | Chief Scientific Officer | Sell | 60,000 | $17.06 | $1,023,600.00 | -7.2% | |
| Mar 14, 2017 | PAHC Phibro Animal Health Corp | Welch Daniel A | Sr VP, Human Resources | Sell | 5,000 | $27.22 | $136,100.00 | -100% | |
| Mar 14, 2017 | BHC Bausch Health Companies Inc. | Herendeen Paul | EVP And CFO | Buy | 24,000 | $10.72 | $257,280.00 | +16.0% | |
| Mar 13, 2017 | PAHC Phibro Animal Health Corp | Carlson Gerald K | Director | Sell | 12,000 | $27.55 | $330,600.00 | -100% | |
| Mar 13, 2017 | BHC Bausch Health Companies Inc. | Pershing Square Capital Management, L.P.74 | Director | Sell | 18,114,432 | $11.00 | $199,258,752.00 | -100% | |
| Mar 13, 2017 | CPIX Cumberland Pharmaceuticals Inc | Lawrence Thomas R | Director | Sell | 20,781 | $6.24 | $129,673.44 | -77.6% | |
| Mar 10, 2017 | BCRX Biocryst Pharmaceuticals Inc | Staab Thomas R II | Senior Vice President And CFO | Sell | 3,250 | $9.06 | $29,445.00 | -2.7% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.